We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+1.17%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.63B
AUM Growth
-$171M
Cap. Flow
-$213M
Cap. Flow %
-13.08%
Top 10 Hldgs %
50.48%
Holding
102
New
12
Increased
17
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$101M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$28.5M
3
NVDQ
Novadaq Technologies Inc.
NVDQ
+$21.2M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$14.3M
5
PETX
Aratana Therapeutics, Inc.
PETX
+$14M

Top Sells

Rank Stock Value
1
EBS icon
Emergent Biosolutions
EBS
+$33.1M
2
NVRO
NEVRO CORP.
NVRO
+$21.7M
3
CSII
Cardiovascular Systems, Inc.
CSII
+$19M
4
MASI
Masimo
MASI
+$16.3M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 78.51%
2 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
76
DELISTED
Cidara Therapeutics
CDTX
$2.86M 0.18%
8,344
– –
NVET
77
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$2.46M 0.15%
+721,595
New +$2.85M
BDSI
78
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.4M 0.15%
500,000
+250,000
+100% +$1.42M
WINT
79
DELISTED
Windtree Therapeutics Inc
WINT
$2.33M 0.14%
777,798
+100,000
+15% +$410K
ARMP icon
80
Armata Pharmaceuticals
ARMP
$171M
$2.2M 0.14%
3,943
– –
VCYT icon
81
Veracyte
VCYT
$4.52B
$2.2M 0.14%
304,980
-431,216
-59% -$2.9M
PHIO icon
82
Phio Pharmaceuticals
PHIO
$12.1M
$1.96M 0.12%
9
-1
-10% -$251K
SSKN
83
DELISTED
Strata Skin Sciences
SSKN
$1.41M 0.09%
25,486
– –
CRDC
84
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$1.37M 0.08%
887,499
– –
AIXC
85
AIxCrypto Holdings Inc
AIXC
$16.6M
$1.32M 0.08%
6
– –
PTN
86
Palatin Technologies
PTN
$13.7M
$908K 0.06%
1,094
– –
ALBO
87
DELISTED
Albireo Pharma Inc
ALBO
$685K 0.04%
66,667
-105,184
-61% -$1.09M
APYX icon
88
Apyx Medical
APYX
$165M
– –
-947,400
Closed -$1.85M
ARAY icon
89
Accuray
ARAY
$28.4M
– –
-750,000
Closed -$3.75M
HRTX icon
90
CALL
Heron Therapeutics
HRTX
$86.3M
– –
-500,000
Closed -$12.2M
IRMD icon
91
iRadimed
IRMD
$1.21B
– –
-230,358
Closed -$5.61M
MASI
92
DELISTED
Masimo
MASI
– –
-421,728
Closed -$16.3M
TVTX icon
93
CALL
Travere Therapeutics
TVTX
$5.33B
– –
-500,000
Closed -$10.1M
NVRO
94
CALL
DELISTED
NEVRO CORP.
NVRO
– –
-200,000
Closed -$9.28M
SPPI
95
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-2,516,748
Closed -$15.1M
CSII
96
DELISTED
Cardiovascular Systems, Inc.
CSII
– –
-1,200,000
Closed -$19M
ZSAN
97
DELISTED
Zosano Pharma Corporation
ZSAN
– –
-531
Closed -$1.47M
FLXN
98
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-323,188
Closed -$4.8M
TTPH
99
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-8,002
Closed -$1.19M
CASC
100
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-98,700
Closed -$1.62M
1 2 3
4
5

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2015 Portfolio in Review

As of Q4 2015, Broadfin Capital held 102 positions worth $1.63B, down 9.5% from $1.8B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Broadfin Capital withdrew a net $213M in Q4 2015, closing 14 positions and reducing 20 holdings. Its most notable exit was Cardiovascular Systems, Inc., an estimated $19M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 63% a quarter earlier, followed by Technology.

Against the trend, Broadfin Capital opened a new position in Bausch Health worth $91.5M.

  • Broadfin Capital's largest Q4 2015 buy was Bausch Health: 900,000 shares worth $91.5M.
  • Broadfin Capital added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015, an estimated $28.5M increase.
  • Broadfin Capital's biggest Q4 2015 reduction was Emergent Biosolutions, cutting an estimated $33.1M.
  • Broadfin Capital fully exited Cardiovascular Systems, Inc. in Q4 2015, selling an estimated $19M.
  • Broadfin Capital's ten largest holdings make up 50% of its $1.63B portfolio in Q4 2015.
  • Broadfin Capital opened 12 new positions and closed 14 in Q4 2015.
  • Broadfin Capital's portfolio value fell 9.5% quarter-over-quarter to $1.63B.

Based on Broadfin Capital's 13F filing for Q4 2015, filed 16 Feb 2016.